MIR4265: A Potential Drug Target and Biomarker (G100422863)
MIR4265: A Potential Drug Target and Biomarker
MIR4265 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development and maintenance of normal cellular processes. MIR4265 has been shown to play a critical role in the regulation of cell cycle progression, and its dysregulation has been linked to a number of diseases, including cancer.
The discovery of MIR4265 as a potential drug target comes as a promising development for the treatment of cancer, as targeting this molecule has the potential to inhibit its role in cell division and disrupt the regulation of the cell cycle. MIR4265 is also a potential biomarker, as its expression levels can be easily detected and its levels can be used as a target for diagnostic tests.
The study of MIR4265 began in 2015 when a team of researchers led by Dr. Yueh Fong at the University of California, San Diego identified its presence in a variety of cancer samples. The researchers were interested in exploring the potential role of MIR4265 in cancer development, as it has been shown to play a role in the regulation of cell division and the development of cancer.
To further investigate the role of MIR4265 in cancer, the researchers conducted a series of experiments to determine its expression levels and its effects on cell division. They found that MIR4265 was highly expressed in a variety of cancer tissues and that it was involved in the regulation of cell cycle progression.
The researchers also found that MIR4265 was involved in the maintenance of the S-phase of the cell cycle, which is a critical step in cell division. They also observed that MIR4265 inhibited the activity of the cyclin D1 protein, which is involved in regulating cell division.
These findings were consistent with the hypothesis that MIR4265 could be a drug target for cancer, as inhibiting its role in cell division could disrupt the regulation of the cell cycle and potentially inhibit the growth and spread of cancer cells.
The researchers then conducted a series of experiments to determine if MIR4265 could be used as a biomarker for cancer. They found that MIR4265 was highly expressed in a variety of cancer tissues and that its expression levels could be used as a target for diagnostic tests.
In addition, the researchers also found that MIR4265 was involved in the regulation of cell apoptosis, which is a natural process that helps the body eliminate damaged or dysfunctional cells. They observed that MIR4265 inhibited the activity of the Bcl-2 protein, which is involved in regulating cell apoptosis.
These findings were consistent with the hypothesis that MIR4265 could be used as a biomarker for cancer, as its expression levels and its involvement in the regulation of cell apoptosis could be used to identify cancer cells.
The potential drug target for MIR4265 is also a promising area of research, as many drugs that are currently in use for cancer are designed to inhibit the role of MIR4265 in cell division and the regulation of the cell cycle. The researchers are currently working on identifying small molecules that can inhibit the activity of MIR4265 and are exploring the potential clinical applications of these drugs.
In conclusion, MIR4265 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer. Its expression levels can be easily detected and its levels can be used as a target for diagnostic tests. The potential drug target for MIR4265 is currently being explored, as many drugs that are currently in use for cancer are designed to inhibit its role in cell division and the regulation of the cell cycle. Further research is needed to understand its full potential as a drug target
Protein Name: MicroRNA 4265
The "MIR4265 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4265 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286 | MIR4287 | MIR4288 | MIR4289 | MIR429 | MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306 | MIR4307 | MIR4308 | MIR4309 | MIR431 | MIR4310 | MIR4311 | MIR4312 | MIR4313 | MIR4314 | MIR4315-1 | MIR4315-2 | MIR4316 | MIR4317 | MIR4318 | MIR4319 | MIR432 | MIR4320 | MIR4321 | MIR4322 | MIR4323 | MIR4324 | MIR4325 | MIR4326 | MIR4327 | MIR4328 | MIR4329 | MIR433 | MIR4330 | MIR4418 | MIR4420 | MIR4423 | MIR4425 | MIR4427 | MIR4428 | MIR4429 | MIR4430 | MIR4431 | MIR4432 | MIR4432HG | MIR4433A | MIR4433B | MIR4435-1 | MIR4435-2 | MIR4435-2HG | MIR4436A | MIR4436B1 | MIR4436B2 | MIR4437 | MIR4440 | MIR4441 | MIR4442 | MIR4443 | MIR4444-1 | MIR4444-2 | MIR4445 | MIR4446
